STYX

Summary

STYX (serine/threonine/tyrosine interacting protein, HGNC:11447) is a protein-coding gene on chromosome 14q22.1, encoding Serine/threonine/tyrosine-interacting protein (Q8WUJ0). Catalytically inactive phosphatase.

The protein encoded by this gene is a pseudophosphatase, able to bind potential substrates but lacking an active catalytic loop. The encoded protein may be involved in spermiogenesis. Two transcript variants encoding the same protein have been found for these genes.

Source: NCBI Gene 6815 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 39 total
• MANE Select transcript: NM_145251

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11447
Approved symbol	STYX
Name	serine/threonine/tyrosine interacting protein
Location	14q22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000198252
Ensembl biotype	protein_coding
OMIM	615814
Entrez	6815

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000354586, ENST00000442123, ENST00000556861, ENST00000874949, ENST00000874950, ENST00000874951, ENST00000874952, ENST00000874953, ENST00000938212, ENST00000964564

RefSeq mRNA: 2 — MANE Select: NM_145251 NM_001130701, NM_145251

CCDS: CCDS9711

Canonical transcript exons

ENST00000354586 — 11 exons

Exon	Start	End
ENSE00000657471	52759682	52759754
ENSE00000854757	52757874	52757924
ENSE00001147757	52744852	52744884
ENSE00001164972	52768840	52768933
ENSE00001165000	52757743	52757782
ENSE00001165010	52757319	52757355
ENSE00001165021	52756551	52756611
ENSE00001165033	52750683	52750780
ENSE00001165045	52746426	52746479
ENSE00001392440	52730166	52730531
ENSE00001958260	52771033	52774989

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 90.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.9716 / max 131.2841, expressed in 1819 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139622	24.9716	1819

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
superficial temporal artery	UBERON:0001614	90.52	gold quality
oviduct epithelium	UBERON:0004804	90.30	gold quality
epithelial cell of pancreas	CL:0000083	89.94	gold quality
vastus lateralis	UBERON:0001379	89.41	gold quality
quadriceps femoris	UBERON:0001377	88.62	gold quality
biceps brachii	UBERON:0001507	87.34	gold quality
leukocyte	CL:0000738	87.10	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.03	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	86.99	gold quality
monocyte	CL:0000576	86.93	gold quality
deltoid	UBERON:0001476	86.61	gold quality
buccal mucosa cell	CL:0002336	86.57	gold quality
mucosa of paranasal sinus	UBERON:0005030	86.48	gold quality
oral cavity	UBERON:0000167	86.27	gold quality
liver	UBERON:0002107	86.10	gold quality
calcaneal tendon	UBERON:0003701	86.08	gold quality
skeletal muscle tissue	UBERON:0001134	86.03	gold quality
right lobe of liver	UBERON:0001114	85.82	gold quality
amniotic fluid	UBERON:0000173	85.52	gold quality
palpebral conjunctiva	UBERON:0001812	85.52	gold quality
muscle tissue	UBERON:0002385	85.05	gold quality
esophagus squamous epithelium	UBERON:0006920	84.80	gold quality
granulocyte	CL:0000094	84.13	gold quality
colonic epithelium	UBERON:0000397	83.83	gold quality
hindlimb stylopod muscle	UBERON:0004252	83.73	gold quality
gingiva	UBERON:0001828	83.67	gold quality
lymph node	UBERON:0000029	83.58	gold quality
muscle of leg	UBERON:0001383	83.26	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.18	gold quality
gastrocnemius	UBERON:0001388	83.16	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

178 targeting STYX, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-8068	99.98	73.85	2376
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817

Literature-anchored findings (GeneRIF, showing 5)

• results identify STYX as an important regulator of ERK1/2 signaling critical for cell migration (PMID:23847209)
• The authors show that STYX binds to the F-box domain of FBXW7 and disables its recruitment into the SCF ubiquitin ligase complex. (PMID:28007894)
• Results suggest that STYX is a pseudophosphatase that uses the ‘competitor’ and ‘anchor’ mode of action to exert its biologic roles. [review] (PMID:28408485)
• STYX bound to the F-box and WD repeat domain-containing7 (FBXW7) protein and inhibited its function. Co-regulation of STYX and FBXW7 expression reversed the biological changes mediated by regulation of STYX expression alone in CRC cells. (PMID:30981757)
• STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway. (PMID:32239181)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	styx	ENSDARG00000057699
mus_musculus	Styx	ENSMUSG00000053205
mus_musculus	Styx-ps	ENSMUSG00000071748
rattus_norvegicus		ENSRNOG00000065797
rattus_norvegicus		ENSRNOG00000090469
caenorhabditis_elegans		WBGENE00021867

Paralogs (31): DUSP13B (ENSG00000079393), DUSP12 (ENSG00000081721), SSH1 (ENSG00000084112), DUSP3 (ENSG00000108861), PTPMT1 (ENSG00000110536), DUSP16 (ENSG00000111266), EPM2A (ENSG00000112425), DUSP22 (ENSG00000112679), DUSP1 (ENSG00000120129), DUSP4 (ENSG00000120875), STYXL1 (ENSG00000127952), DUSP9 (ENSG00000130829), DUSP26 (ENSG00000133878), DUSP5 (ENSG00000138166), DUSP6 (ENSG00000139318), SSH2 (ENSG00000141298), DUSP10 (ENSG00000143507), DUSP15 (ENSG00000149599), DUSP2 (ENSG00000158050), KASH5 (ENSG00000161609), DUSP19 (ENSG00000162999), DUSP7 (ENSG00000164086), DUSP18 (ENSG00000167065), SSH3 (ENSG00000172830), DUSP8 (ENSG00000184545), DUSP28 (ENSG00000188542), DUSP29 (ENSG00000188716), DUSP21 (ENSG00000189037), STYXL2 (ENSG00000198842), DUSP14 (ENSG00000276023), DUSP13A (ENSG00000293543)

Protein

Protein identifiers

Serine/threonine/tyrosine-interacting protein — Q8WUJ0 (reviewed: Q8WUJ0)

Alternative names: Inactive tyrosine-protein phosphatase STYX, Phosphoserine/threonine/tyrosine interaction protein

All UniProt accessions (1): Q8WUJ0

UniProt curated annotations — full annotation on UniProt →

Function. Catalytically inactive phosphatase. Acts as a nuclear anchor for MAPK1/MAPK3 (ERK1/ERK2). Modulates cell-fate decisions and cell migration by spatiotemporal regulation of MAPK1/MAPK3 (ERK1/ERK2). By binding to the F-box of FBXW7, prevents the assembly of FBXW7 into the SCF E3 ubiquitin-protein ligase complex, and thereby inhibits degradation of its substrates. Plays a role in spermatogenesis.

Subunit / interactions. Interacts with MAPK1; independently of MAPK1 phosphorylation status. Interacts with CARHSP1/Crhsp-24. Interacts (via FQQ motif) with FBXW7 isoforms 1 (via F-box domain) and 3 (via F-box domain); the interaction is direct and prevents FBXW7 interaction with SKP1, a component of the SCF(FBXW7) complex. Does not interact with FBXW7 isoform 2.

Subcellular location. Nucleus. Cytoplasm. Cytosol.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class subfamily.

RefSeq proteins (2): NP_001124173, NP_660294* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000340	Dual-sp_phosphatase_cat-dom	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR020422	TYR_PHOSPHATASE_DUAL_dom	Domain
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR052449	STYX-Interacting_Phosphatase	Family

Pfam: PF00782

UniProt features (27 total): helix 9, strand 6, modified residue 3, mutagenesis site 3, turn 2, chain 1, domain 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2R0B	X-RAY DIFFRACTION	1.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WUJ0-F1	87.74	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 184, 193, 201

Mutagenesis-validated functional residues (3):

Position	Phenotype
76–78	loss of interaction with fbxw7. does not affect interaction with mapk1 and nuclear localization.
120	confers phosphatase activity. dephosphorylates mapk1. does not affect interaction with fbxw7 and nuclear localization.
142–144	increases interaction with fbxw7.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 200 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, HORIUCHI_WTAP_TARGETS_DN, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_REGULATION_OF_PROTEIN_BINDING, TGCACTT_MIR519C_MIR519B_MIR519A, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, TATTATA_MIR374, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GTGCCTT_MIR506, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_BINDING, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_REGULATION_OF_CATABOLIC_PROCESS, ATTACAT_MIR3803P

GO Biological Process (5): negative regulation of protein binding (GO:0032091), negative regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process (GO:0062026), regulation of ERK1 and ERK2 cascade (GO:0070372), protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311)

GO Molecular Function (3): pseudophosphatase activity (GO:0001691), F-box domain binding (GO:1990444), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein binding	1
regulation of protein binding	1
negative regulation of binding	1
SCF-dependent proteasomal ubiquitin-dependent protein catabolic process	1
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	1
regulation of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process	1
regulation of MAPK cascade	1
ERK1 and ERK2 cascade	1
dephosphorylation	1
protein modification process	1
phosphate-containing compound metabolic process	1
phosphatase inhibitor activity	1
protein domain specific binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1346 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STYX	TXNDC16	Q9P2K2	576
STYX	GNPNAT1	Q96EK6	565
STYX	GPR137C	Q8N3F9	548
STYX	CUL1	Q13616	495
STYX	DDHD1	Q8NEL9	489
STYX	GPR27	Q9NS67	467
STYX	PTS	Q03393	461
STYX	SKP1	P34991	458
STYX	FAXDC2	Q96IV6	450
STYX	MAPK1	P28482	442
STYX	MAPK3	P27361	442
STYX	RTRAF	Q9Y224	438
STYX	PSMC6	P49719	427
STYX	SHOC2	Q9UQ13	426
STYX	MYC	P01106	411

IntAct

43 interactions, top by confidence:

A	B	Type	Score
FBXW7	MYC	psi-mi:“MI:0914”(association)	0.870
FBXW7	SKP1	psi-mi:“MI:0914”(association)	0.860
FBXW7	SKP1	psi-mi:“MI:0915”(physical association)	0.860
LAMTOR2	LAMTOR5	psi-mi:“MI:0914”(association)	0.860
POLR2J	POLR1C	psi-mi:“MI:0914”(association)	0.830
STYX	FBXW7	psi-mi:“MI:0915”(physical association)	0.760
STYX	FBXW7	psi-mi:“MI:0407”(direct interaction)	0.760
STYX	FBXW7	psi-mi:“MI:0915”(physical association)	0.600
STYX	FBXW7	psi-mi:“MI:0403”(colocalization)	0.600
STYX	FBXW7	psi-mi:“MI:0403”(colocalization)	0.460
STYX	FBXW7	psi-mi:“MI:0915”(physical association)	0.460
GARIN1B	STYX	psi-mi:“MI:0915”(physical association)	0.400
STYX	LMTK2	psi-mi:“MI:0915”(physical association)	0.370
STYX	AATK	psi-mi:“MI:0915”(physical association)	0.370
STYX	ERBB4	psi-mi:“MI:0915”(physical association)	0.370
STYX	ERBB2	psi-mi:“MI:0915”(physical association)	0.370
STYX	EGFR	psi-mi:“MI:0915”(physical association)	0.370
STYX	ERBB3	psi-mi:“MI:0915”(physical association)	0.370
STYX	TEK	psi-mi:“MI:0915”(physical association)	0.370
STYX	KIT	psi-mi:“MI:0915”(physical association)	0.370
STYX	KDR	psi-mi:“MI:0915”(physical association)	0.370
STYX	ROR1	psi-mi:“MI:0915”(physical association)	0.370
STYX	ROR2	psi-mi:“MI:0915”(physical association)	0.370
STYX	MUSK	psi-mi:“MI:0915”(physical association)	0.370
STYX	INSRR	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (102): FAM172A (Affinity Capture-MS), FBXL12 (Affinity Capture-MS), FBXL14 (Affinity Capture-MS), FBXO33 (Affinity Capture-MS), FBXO38 (Affinity Capture-MS), FBXW7 (Affinity Capture-MS), HDLBP (Affinity Capture-MS), HSPA6 (Affinity Capture-MS), KPNA1 (Affinity Capture-MS), PAK4 (Affinity Capture-MS), SF3B4 (Affinity Capture-MS), SKP1 (Affinity Capture-MS), USP7 (Affinity Capture-MS), STYX (Affinity Capture-MS), CAP1 (Affinity Capture-MS)

ESM2 similar proteins: A4FUN7, A5D9H7, A5PKA5, A5WWB0, A6H8I0, A6NNY8, C0HB46, D0RB01, F1M625, O75317, O89050, P0C8Z3, P50876, P50904, P62068, P62069, Q09LZ8, Q3TIX9, Q3UHD6, Q52KZ6, Q53GS9, Q5DU02, Q5F415, Q5F450, Q5IFJ9, Q5IS37, Q5IS82, Q5M981, Q5R4Q7, Q5R573, Q5R761, Q5RB35, Q5RBQ4, Q5RDP3, Q5VU57, Q60969, Q6DCJ1, Q6GNI6, Q8CEG8, Q8K4V4

Diamond homologs: A4IHU7, F1QWM2, O09112, O13632, O55737, O95147, P0C591, P0C592, P0C593, P0C594, P0C595, P0C596, P0C597, P0C598, P0C599, P0C5A0, P0C5A1, P0C5A2, P28562, P28563, P51452, Q05922, Q13115, Q13202, Q148W8, Q16828, Q16829, Q17QJ3, Q17QM8, Q1LWL2, Q29RA3, Q2KJ36, Q39491, Q4KL92, Q4RQD3, Q4V7N3, Q54T76, Q54Y32, Q556Y8, Q55BI8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
STYX	“down-regulates activity”	FBXW7	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by Aberrant PI3K in Cancer	5	21.9×	9e-05
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	6	20.0×	2e-05
PIP3 activates AKT signaling	8	18.4×	3e-06
RAF/MAP kinase cascade	7	14.7×	2e-05
Cellular responses to stress	7	8.9×	2e-04
Cellular responses to stimuli	7	7.6×	6e-04

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor protein tyrosine kinase signaling pathway	10	51.1×	2e-12
positive regulation of epithelial cell proliferation	5	35.9×	3e-05
protein autophosphorylation	7	29.9×	5e-07
positive regulation of MAPK cascade	10	23.7×	2e-09
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	8	18.4×	1e-06
positive regulation of cell migration	7	12.7×	7e-05
cell migration	7	12.7×	7e-05
positive regulation of ERK1 and ERK2 cascade	5	12.5×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1741 predictions. Top by Δscore:

Variant	Effect	Δscore
14:52730528:CGAGG:C	donor_loss	1.0000
14:52730531:GGT:G	donor_loss	1.0000
14:52730532:GT:G	donor_loss	1.0000
14:52730533:T:A	donor_loss	1.0000
14:52744837:T:G	acceptor_gain	1.0000
14:52750777:TTAGG:T	donor_loss	1.0000
14:52750778:TAGGT:T	donor_loss	1.0000
14:52750779:AGGT:A	donor_loss	1.0000
14:52750780:GGT:G	donor_loss	1.0000
14:52750781:GT:G	donor_loss	1.0000
14:52750782:T:G	donor_loss	1.0000
14:52757872:A:AG	acceptor_gain	1.0000
14:52757873:G:GG	acceptor_gain	1.0000
14:52759673:T:TA	acceptor_gain	1.0000
14:52759680:A:AC	acceptor_loss	1.0000
14:52759680:A:AG	acceptor_gain	1.0000
14:52759681:G:GT	acceptor_gain	1.0000
14:52759681:GA:G	acceptor_gain	1.0000
14:52759681:GAGA:G	acceptor_gain	1.0000
14:52759681:GAGAT:G	acceptor_gain	1.0000
14:52759753:AGG:A	donor_loss	1.0000
14:52759754:GGTAA:G	donor_loss	1.0000
14:52759756:T:A	donor_loss	1.0000
14:52768834:TTTTA:T	acceptor_loss	1.0000
14:52768835:TTTA:T	acceptor_loss	1.0000
14:52768836:TTAG:T	acceptor_loss	1.0000
14:52768837:TA:T	acceptor_loss	1.0000
14:52768838:A:AG	acceptor_gain	1.0000
14:52768838:A:T	acceptor_loss	1.0000
14:52768839:G:GC	acceptor_loss	1.0000

AlphaMissense

1480 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:52744855:T:A	W21R	1.000
14:52744855:T:C	W21R	1.000
14:52744857:G:C	W21C	1.000
14:52744857:G:T	W21C	1.000
14:52744871:G:C	R26T	1.000
14:52744872:A:C	R26S	1.000
14:52744872:A:T	R26S	1.000
14:52746450:G:C	G39R	1.000
14:52746451:G:A	G39D	1.000
14:52750724:C:G	C62W	1.000
14:52750729:G:C	R64P	1.000
14:52756573:G:C	D89H	1.000
14:52756573:G:T	D89Y	1.000
14:52756574:A:C	D89A	1.000
14:52756574:A:G	D89G	1.000
14:52756574:A:T	D89V	1.000
14:52757752:T:C	L117P	1.000
14:52757760:G:A	G120R	1.000
14:52757760:G:C	G120R	1.000
14:52757769:G:A	G123R	1.000
14:52757769:G:C	G123R	1.000
14:52757769:G:T	G123W	1.000
14:52757770:G:A	G123E	1.000
14:52757770:G:T	G123V	1.000
14:52757776:C:T	S125F	1.000
14:52757891:C:A	A133E	1.000
14:52759699:T:A	V150D	1.000
14:52759711:G:C	R154T	1.000
14:52759712:A:C	R154S	1.000
14:52759712:A:T	R154S	1.000

dbSNP variants (sampled 300 via entrez): RS1000054381 (14:52761242 C>A,T), RS1000094738 (14:52770880 T>A), RS1000109847 (14:52760870 C>T), RS1000196420 (14:52774326 T>C), RS1000228518 (14:52731185 G>T), RS1000229070 (14:52774686 A>G), RS1000279639 (14:52732062 A>C,G), RS1000358385 (14:52737360 G>A), RS1000391986 (14:52767855 A>G,T), RS1000504115 (14:52754034 C>A), RS1000513955 (14:52742498 C>T), RS1000609136 (14:52749337 C>T), RS1000628282 (14:52755672 T>G), RS1000640189 (14:52749625 C>A,T), RS1000643715 (14:52736415 G>A)

Disease associations

OMIM: gene MIM:615814 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001942_15	Prostate cancer	2.000000e-14

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression, affects expression	4
Cyclosporine	decreases expression	3
methylmercuric chloride	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Folic Acid	decreases expression	1
Hydralazine	increases expression, affects cotreatment	1
Indomethacin	affects cotreatment, increases expression	1
Methyl Methanesulfonate	increases expression	1
Quercetin	decreases expression	1
Thimerosal	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects cotreatment, increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9TH	Ubigene HEK293 STYX KO	Transformed cell line	Female
CVCL_E0QC	Ubigene HeLa STYX KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.